Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia

NCT01251627 ·Status: COMPLETED ·Phase: PHASE2

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

NCT01849276 ·Status: TERMINATED ·Phase: PHASE1

Molecular Diagnostic Platform for AML

NCT04446741 ·Status: UNKNOWN

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

NCT03367299 ·Status: COMPLETED ·Phase: PHASE2

Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia

NCT07146542 ·Status: NOT_YET_RECRUITING

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

NCT03075969 ·Status: UNKNOWN

"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"

NCT05543161 ·Status: UNKNOWN

Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies

NCT07189117 ·Status: RECRUITING

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

NCT02768792 ·Status: COMPLETED ·Phase: PHASE2

Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)

NCT07060612 ·Status: ACTIVE_NOT_RECRUITING

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02437019 ·Status: APPROVED_FOR_MARKETING

Role of BCL-B in Multiple Myeloma

NCT01270009 ·Status: COMPLETED

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

NCT00462761 ·Status: COMPLETED ·Phase: PHASE1

A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece

NCT04159779 ·Status: ACTIVE_NOT_RECRUITING

Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients

NCT06651866 ·Status: RECRUITING ·Phase: PHASE1

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05673057 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Maintenance Venetoclax in AML Fit Patients

NCT07244367 ·Status: RECRUITING ·Phase: NA

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01804101 ·Status: COMPLETED ·Phase: NA

Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer

NCT05035615 ·Status: COMPLETED

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

NCT00449761 ·Status: TERMINATED ·Phase: PHASE2

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

NCT00896129 ·Status: COMPLETED

LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION

NCT07313982 ·Status: RECRUITING

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

NCT01841723 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

NCT04272957 ·Status: UNKNOWN ·Phase: PHASE1